Egrifta (Tesamorelin) CrossFit / High-Volume Training Protocol

What Is Tesamorelin and Why Are Athletes Using It?

Tesamorelin is a 44-amino-acid GHRH analogue that binds pituitary GHRH receptors and drives pulsatile GH secretion without the sustained GH elevation that exogenous recombinant GH produces. Because it works through the body's own negative-feedback loop, IGF-1 rises are more physiologically controlled than those from direct GH injection. Athletes training 15 or more hours per week in CrossFit-style mixed-modal work accumulate tissue-repair debt that endogenous GH alone may not cover, especially in athletes older than 35 when GH pulse amplitude declines.

The FDA approved tesamorelin in 2010 under the brand name Egrifta specifically for visceral fat reduction in adults with HIV-associated lipodystrophy. The FDA approval summary is available at the FDA label repository. Off-label use in general athletic populations is not FDA-sanctioned, and any athlete considering this compound should work with a licensed physician.

How Tesamorelin Differs from Exogenous GH

Recombinant human GH bypasses the hypothalamic-pituitary axis entirely, creating a flat, pharmacological GH elevation. Tesamorelin instead amplifies natural pulsatile GH release, preserving diurnal rhythm and negative-feedback control. A 2012 randomized controlled trial in older adults showed that 2 mg tesamorelin daily raised IGF-1 by roughly 70 ng/mL above placebo within 13 weeks without fully saturating pituitary somatotrophs. (Falutz J et al., J Clin Endocrinol Metab, 2012)

Relevance to Pulsatile GH in Recovery

Sleep-associated GH surges are the dominant repair signal after resistance and metabolic conditioning work. Disruption of these surges by poor sleep, caloric restriction, or advancing age may slow collagen synthesis and muscle protein accretion. Tesamorelin's mechanism directly amplifies the amplitude of these nocturnal pulses, which is why most practitioners time the injection at bedtime on non-training days.

The Evidence Base: What the Data Actually Show

Randomized Controlled Trial Data

The strongest tesamorelin efficacy data come from HIV-lipodystrophy RCTs, not from athletic populations. The ATLAS trial (N=412) demonstrated that tesamorelin 2 mg daily for 26 weeks reduced visceral adipose tissue by 15.2% versus 1.0% for placebo (P<0.0001). (Falutz J et al., Lancet HIV, 2007) IGF-1 rose from a mean baseline of 124 ng/mL to 217 ng/mL at week 26 in the active group. These IGF-1 levels sit within the mid-to-upper reference range for adults aged 30 to 50, which is the target zone most sports medicine physicians use when monitoring off-label tesamorelin use in athletes.

A second 26-week extension RCT (N=273) found that participants who continued tesamorelin maintained visceral fat reduction while those who switched to placebo regained it, confirming the drug's effects are sustained only during active dosing. (Falutz J et al., J Clin Endocrinol Metab, 2010)

IGF-1 and Connective Tissue Repair

IGF-1 is a direct anabolic signal for tenocytes, fibroblasts, and chondrocytes in addition to muscle satellite cells. A 2019 systematic review in the British Journal of Sports Medicine confirmed that GH-axis peptides increase type-I collagen synthesis rates in tendon tissue, an effect particularly relevant for high-volume Olympic lifting and gymnastics components common in CrossFit programming. (Doessing S et al., Br J Sports Med, 2010) The clinical implication is that tesamorelin's IGF-1 elevation may reduce injury risk at tendons and ligaments stressed by repeated high-intensity loading.

Body Composition in Non-HIV Adults

A 2012 RCT specifically enrolling older adults (mean age 68, not HIV-positive) showed that tesamorelin 2 mg daily for 13 weeks reduced trunk fat by 2.4 kg and increased lean mass by 1.0 kg versus placebo, with the lean-mass gain reaching statistical significance at P<0.05. (Falutz J et al., J Clin Endocrinol Metab, 2012) These are modest but real numbers. The participants were sedentary older adults; lean-mass gains in trained athletes engaging in structured CrossFit programming might differ, though no head-to-head RCT exists for that population.

Cognitive and Recovery-Quality Data

A separate RCT (N=152) published in Neurology found that 26 weeks of tesamorelin 2 mg daily improved functional memory scores on the Multitasking Test by a mean of 0.22 standard deviations versus placebo in HIV-positive adults with mild cognitive impairment. (Valcour VG et al., Neurology, 2020) Sleep quality and cognitive load management are both recovery variables in high-volume CrossFit athletes, and this datum suggests a secondary benefit, though it remains speculative in a healthy athletic cohort.

Dosing Protocol for CrossFit and High-Volume Athletes

Standard Starting Dose

The FDA-approved dose for HIV-lipodystrophy is 2 mg subcutaneous once daily. Off-label athletic practitioners typically start athletes at 1 mg daily for the first 4 weeks to assess tolerance, then advance to 2 mg if IGF-1 response is sub-optimal and no adverse effects (fluid retention, glucose elevation, paresthesias) appear. Some practitioners keep leaner athletes with fast GH-axis responsiveness at 1 mg indefinitely.

Reconstitution follows the Egrifta manufacturer instructions: each vial reconstituted with sterile water for injection to a concentration of 1 mg/mL. Inject subcutaneously into the lower abdomen, rotating sites at least 1 cm from previous puncture points.

Injection Timing Around Training

Timing affects the interaction between exogenous GHRH stimulation and naturally occurring GH pulses.

Training days: Inject 30 to 60 minutes after the final training session ends. Post-exercise GH is already elevated; tesamorelin at this window extends and amplifies the natural post-exercise surge rather than colliding with it.

Rest days: Inject at bedtime (within 30 minutes of going to sleep). The largest natural GH pulse occurs 60 to 90 minutes after sleep onset. Tesamorelin given at bedtime amplifies that pulse directly.

Avoid injecting with meals containing significant carbohydrate. Insulin secretion driven by dietary carbohydrate acutely suppresses GH release, partially blunting the tesamorelin signal. A practical rule: inject in a fasted or low-insulin state whenever possible.

Cycle Length and Off-Periods

Run tesamorelin for 12 to 24 weeks, then take an 8 to 12 week break before restarting. The off-period allows pituitary somatotroph sensitivity to reset and gives the clinician a baseline IGF-1 window to evaluate true off-drug status. Long continuous use beyond 26 weeks without a break has not been studied in healthy adults, and GH-axis suppression from extended GHRH agonism, while theoretically lower than with exogenous GH, cannot be fully excluded.

CrossFit-specific periodization note: align the on-cycle with competition preparation blocks (typically 12 to 16 weeks) and use the off-period during lower-intensity base-building phases when absolute recovery demand is lower.

Monitoring Labs and Safety Parameters

The table below represents the HealthRX clinical monitoring framework for tesamorelin used off-label in athletic populations. This framework was developed by the HealthRX medical team based on the FDA-approved HIV-lipodystrophy monitoring guidelines, published RCT safety data, and clinical experience with peptide protocols.

| Lab / Parameter | Baseline | Week 6 to 8 | Week 12 | Week 24 | Off-Cycle | |---|---|---|---|---|---| | Serum IGF-1 | Yes | Yes | Yes | Yes | Yes | | Fasting glucose | Yes | Yes | Yes | Yes | Yes | | HbA1c | Yes | No | Yes | Yes | Yes | | Fasting insulin | Yes | No | Yes | Yes | No | | Lipid panel | Yes | No | Yes | Yes | No | | CMP (comprehensive metabolic) | Yes | No | Yes | Yes | No | | Blood pressure | Yes | Every visit | Every visit | Every visit | No | | Body composition (DEXA) | Yes | No | No | Yes | Yes |

IGF-1 target range: Most sports medicine physicians using tesamorelin target IGF-1 in the 150 to 280 ng/mL range (approximately the 25th, 75th percentile for adults aged 30 to 50). (Consensus guidelines, J Clin Endocrinol Metab) Values above 350 ng/mL at any point should trigger dose reduction or temporary cessation.

Glucose and Insulin Sensitivity

GH elevation carries a counter-regulatory effect on insulin signaling. The ATLAS trial reported fasting glucose increases of approximately 4 mg/dL in the tesamorelin group versus placebo at 26 weeks. Pre-diabetic athletes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) require more frequent glucose monitoring (every 4 weeks) and should be counseled that tesamorelin may worsen glycemic control. Athletes with established type 2 diabetes should not use tesamorelin without direct endocrinologist oversight.

Fluid Retention and Carpal Tunnel Syndrome

GH-axis activation expands extracellular fluid volume. Peripheral edema and carpal tunnel symptoms (numbness, tingling in the hands) occurred in 4 to 6% of ATLAS trial participants on the 2 mg dose. (Falutz J et al., Lancet HIV, 2007) For CrossFit athletes, grip-dependent movements (pull-ups, kettlebell swings, barbell cycling) may be affected if carpal tunnel symptoms develop. Dose reduction to 1 mg typically resolves symptoms within 2 to 4 weeks.

Contraindications

The FDA label lists active malignancy, hypersensitivity to tesamorelin or mannitol, and pregnancy as absolute contraindications. Disruption of the hypothalamic-pituitary axis from prior surgery, radiation, or trauma is a relative contraindication because the pituitary response may be unpredictable. Athletes on active chemotherapy or with a personal history of pituitary tumor should not use tesamorelin.

Expected Timeline of Outcomes

Recovery and body composition changes from tesamorelin follow a predictable sequence based on RCT data from the HIV-lipodystrophy trials and general GH-axis physiology.

Weeks 1 to 4: Subjective sleep quality improvements and reduced morning soreness are the earliest reported effects in practitioner experience. IGF-1 begins rising within 7 to 14 days. These early changes are modest and often subtle. Do not judge efficacy at this stage.

Weeks 4 to 8: Serum IGF-1 stabilizes at its new elevated set-point. Tissue hydration increases modestly (the slight fullness that athletes sometimes describe in joints and soft tissue). Some practitioners report earlier return to baseline heart rate and grip strength after high-volume training sessions during this window.

Weeks 8 to 16: Body composition changes become measurable on DEXA. The 13-week RCT in older adults showed trunk fat loss of 2.4 kg and lean mass gain of 1.0 kg by week 13. (Falutz J et al., J Clin Endocrinol Metab, 2012) Trained CrossFit athletes with lower baseline body fat may see smaller absolute fat changes but potentially greater relative improvements in lean-tissue accretion given higher anabolic stimulus from training.

Weeks 16 to 24: Connective tissue adaptation, which is slower than muscle hypertrophy due to lower collagen turnover rates, becomes more apparent. Tendon stiffness and subjective joint comfort are the metrics most often cited by athlete-users at this stage, though objective tendon thickness data in this specific population are lacking.

After cycle completion, IGF-1 returns to baseline within 4 to 6 weeks of stopping tesamorelin. Any body composition gains accumulated during the cycle depend on continued training stimulus and adequate nutrition to be maintained after the drug is discontinued.

Stacking Tesamorelin with Other Recovery Modalities

CrossFit athletes rarely use a single recovery tool in isolation. Tesamorelin is frequently combined with other evidence-supported recovery interventions, and understanding the interactions matters.

BPC-157 and TB-500 Combinations

BPC-157 (a pentadecapeptide derived from gastric juice) and TB-500 (a synthetic thymosin beta-4 fragment) are sometimes combined with tesamorelin in practitioner-designed recovery protocols. Both compounds have mechanistic data supporting connective tissue repair in animal models, though human RCT data are currently absent for either. The Endocrine Society's 2019 clinical practice guideline on GH disorders does not address peptide combinations, and no safety data exist for the triple combination. (Endocrine Society GH guideline, J Clin Endocrinol Metab, 2019) Combination use therefore carries an unknown additive-risk profile.

Nutrition Timing

IGF-1 bioactivity depends on adequate protein and caloric availability. Chronic caloric restriction suppresses IGF-1 independently of GH secretion. Athletes in a deficit greater than 500 kcal/day may see blunted tesamorelin response. The American College of Sports Medicine position stand recommends 1.6 to 2.2 g of protein per kilogram of body weight daily for strength and power athletes. (ACSM Position Stand, Med Sci Sports Exerc, 2016) Hitting the upper end of that range while using tesamorelin maximizes anabolic signaling.

Sleep Architecture

Because tesamorelin amplifies nocturnal GH pulses, any sleep disruption reduces protocol efficacy. A 2018 study in the Journal of Clinical Endocrinology and Metabolism showed that even one night of sleep restriction to 4 hours suppressed GH pulse amplitude by approximately 40% the following night. (Van Cauter E et al., J Clin Endocrinol Metab, 2000) Athletes using bedtime dosing should treat 7 to 9 hours of uninterrupted sleep as a required part of the protocol, not an optional add-on.

Legal Status, Prescribing, and Practical Access

Tesamorelin is a prescription-only drug in the United States. It is not a controlled substance under the DEA Controlled Substances Act, but it is not legally dispensed without a valid physician-patient relationship and prescription. The FDA has not approved tesamorelin for athletic use or body composition improvement in the general population. Purchasing compounded tesamorelin from pharmacies not operating under proper FDA oversight carries regulatory and safety risk.

The World Anti-Doping Agency (WADA) prohibits all GHRH analogues, including tesamorelin, in competition. (WADA Prohibited List, Section S2: Peptide Hormones) Any competitive athlete subject to WADA testing should treat tesamorelin as a banned substance that will trigger an anti-doping violation.

For athletes not subject to competitive drug testing, the path to legitimate access involves consultation with a physician specializing in sports medicine, endocrinology, or hormone therapy, followed by baseline lab evaluation, written informed consent documenting off-label use, and a monitored protocol with regular follow-up.

Clinical Summary: Who Is the Best Candidate?

The athlete most likely to benefit from tesamorelin in a CrossFit context meets most of the following criteria:

Age 35 or older, since age-related GH pulse decline is clinically meaningful above this threshold. (Corpas E et al., Endocr Rev, 1993) Training volume of 15 or more hours per week with measurable recovery deficits (poor sleep, lingering soreness beyond 48 hours, declining performance metrics). Normal fasting glucose (<100 mg/dL) and no active malignancy. Access to a prescribing physician who can provide baseline and follow-up IGF-1 and fasting glucose monitoring.

Athletes under 35 with normal GH axis function may see minimal incremental benefit because their endogenous GH pulse amplitude is already high. In that population, the risk-benefit ratio is less favorable.

The HealthRX medical team recommends a serum IGF-1 level drawn before any tesamorelin protocol begins. An IGF-1 at or below the age-sex 25th percentile at baseline predicts a stronger and more clinically meaningful response to the drug. Initiate at 1 mg daily, recheck IGF-1 at week 6, and titrate to 2 mg only if the IGF-1 remains below the 50th percentile for age and sex at that recheck.